Phase III Study Compares Combination Therapies in Previously Untreated CLL

Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, speaks about results of a phase III study.

The study evaluated ibrutinib plus obinutuzumab and venetoclax versus ibrutinib plus obinutuzumab in patients who were older and had previously untreated chronic lymphocytic leukemia.

Dr. Woyach and colleagues presented the study’s results during the 2023 American Society of Clinical Oncology Annual Meeting.